

# Cell-Based and Biochemical Structure-Activity Analyses of Analogues of the Microtubule Stabilizer Dictyostatin

Brianne S. Raccor, Andreas Vogt, Rachel P. Sikorski, Charitha Madiraju,  
Raghavan Balachandran, Kia Montgomery, Youseung Shin, Yoshikazu Fukui,  
Won-Hyuk Jung, Dennis P. Curran, and Billy W. Day

Departments of Chemistry (B.S.R., Y.S., Y.F., W.-H.J., D.P.C., B.W.D.), Pharmacology (A.V., R.P.S.), Drug Discovery Institute (A.V., K.M., B.W.D.), and Department of Pharmaceutical Sciences (C.M., R.B., B.W.D.), University of Pittsburgh, Pittsburgh, Pennsylvania

## ABSTRACT

Compounds that bind to microtubules (MTs) and alter their dynamics are highly sought as a result of the clinical success of paclitaxel and docetaxel. The naturally occurring compound (–)-dictyostatin binds to MTs, causes cell cycle arrest in G<sub>2</sub>/M at nanomolar concentrations, and retains antiproliferative activity in paclitaxel-resistant cell lines, making dictyostatin an attractive candidate for development as an antineoplastic agent. In this study, we examined a series of dictyostatin analogues to probe biological and biochemical structure-activity relationships. We used a high-content multiparameter fluorescence-based cellular assay for MT morphology, chromatin condensation, mitotic arrest, and cellular toxicity to identify regions of dictyostatin that were essential for biological activity. Four analogues (6-*epi*-dictyostatin, 7-*epi*-dictyostatin, 16-normethyldictyostatin, and 15Z,16-normethyldictyostatin) retained low nanomolar activity in the cell-based assay and were chosen for analyses with

isolated tubulin. All four compounds were potent inducers of MT assembly. Equilibrium binding constant (*K<sub>i</sub>*) determinations using [<sup>14</sup>C]epothilone B, which has a 3-fold higher affinity for the taxoid binding site than paclitaxel, indicated that 6-*epi*-dictyostatin and 7-*epi*-dictyostatin displaced [<sup>14</sup>C]epothilone B with *K<sub>i</sub>* values of 480 and 930 nM, respectively. 16-Normethyldictyostatin and 15Z,16-normethyldictyostatin had reduced affinity (*K<sub>i</sub>* values of 4.55 and 4.47 μM, respectively), consistent with previous reports showing that C16-normethyldictyostatin loses potency in paclitaxel-resistant cell lines that have a Phe270-to-Val mutation in the taxoid binding site of β-tubulin. Finally, we developed a set of quantitative structure-activity relationship equations correlating structures with antiproliferative activity. The equations accurately predicted biological activity and will help in the design of future analogues.

Microtubules (MTs) are formed from the heterodimeric protein tubulin. Tubulin is composed of two 50-kDa subunits, α- and β-tubulin, which share significant sequence homology (Howard and Hyman, 2003). The importance of MTs for mitosis and the potential to interfere with the delicate dynamics of MTs has led to the search for and development of many tubulin- and MT-interacting compounds. MT-perturbing agents can be roughly classified into two groups based upon the mechanism by which they disrupt normal microtubule function. These include agents that stabilize MT polymer formation and agents that destabilize MTs or inhibit MT polymer formation. The first discovered example of the former class is paclitaxel (Taxol) (Schiff et al., 1979), which has been used successfully in

the treatment of breast, lung, and ovarian carcinomas (Jordan and Wilson, 2004).

Since the discovery of paclitaxel, many other MT stabilizers have been identified from various natural sources, including discodermolide (Gunasekera et al., 1990), dictyostatin (Pettit et al., 1994), the epothilones (Bollag et al., 1995), cyclostreptin (Sato et al., 2000), peloruside A (Hood et al., 2002), and laulimalide (Mooberry et al., 1999). Except for laulimalide and peruloside A (Pryor et al., 2002; Gaitanos et al., 2004), all of these agents share a common binding site on β-tubulin. Of these agents, dictyostatin and discodermolide have the greatest affinity for the taxoid binding site, followed by epothilone B (Madiraju et al., 2005) [epothilone B (EP0906; generic name patupilone) is currently in phase II/III development for a number of different indications]. In addition, all of these agents retain activity against paclitaxel-resistant cell lines (Kowalski et al., 1997; Edler et al., 2005).

This work was supported by National Institutes of Health grant CA078039. Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>. doi:10.1124/mol.107.042598.

**ABBREVIATIONS:** MT, microtubule; SAR, structure-activity relationship; QSAR, quantitative structure-activity relationship; FITC, fluorescein isothiocyanate; DMSO, dimethylsulfoxide; MSG, monosodium glutamate; MDEC, minimum detectable effective concentration; GFA, genetic function approximation.

The structure of dictyostatin remained unknown for a decade because of the scarcity of the compound. Finally in 2004, its structure was elucidated from high-field NMR and computational analyses (Paterson et al., 2004b) and was independently verified by two full syntheses (Paterson et al., 2004a; Shin et al., 2004). The chemical structure of dictyostatin closely resembles that of discodermolide, and 10 of the 11 stereocenters in dictyostatin are shared with discodermolide.

We previously showed dictyostatin to be as potent as discodermolide in terms of MT nucleation ability and competition with [ $^3\text{H}$ ]paclitaxel for binding to the taxoid site on MTs (Madiraju et al., 2005). Structure-activity relationship (SAR) studies to search for the minimum structural elements that contribute to cytotoxicity and retain affinity for the taxoid site were applied here to dictyostatin analogs. A few analogs of dictyostatin and their relative potencies against several cancer cell lines have been reported by others (Paterson and Gardner, 2007; Paterson et al., 2007). We have synthesized several analogs in attempts to study the SAR of the dictyostatin scaffold (Fukui et al., 2006; Jung et al., 2007; Shin et al., 2007). From this collection of existing dictyostatin analogs, we chose several of them based on the structural differences between dictyostatin and discodermolide for detailed biological SAR studies (Fig. 1). The C1–C9 chain is one of the main struc-

tural differences between the two natural products, and analogs designed for this purpose were epimers at C6, C7 and C9, and C2:C3 geometric isomers. From discodermolide SAR studies, it has been established that removal of the C14 methyl group does not decrease cytotoxicity in the cancer cell lines tested. However, when C14-normethyldiscodermolide was tested in paclitaxel-resistant cell lines, cytotoxicity was greatly diminished, with  $\text{IC}_{50}$  values in the micromolar range (Smith et al., 2005). Because discodermolide can be considered an open chain form of the macrolactone of dictyostatin, a 16-*epi* open chain methyl ester analog of the latter was included in our analysis. Finally, we made dictyostatin analogs containing a C15–C16 *Z*-alkene because discodermolide possesses a C13–C14 *Z*-alkene, which is missing in dictyostatin, and two 20-member macrolactone iso analogs (Shin et al., 2005, 2007; Fukui et al., 2006; Jung et al., 2007).

To examine in detail the effects of these targeted structural modifications on biological activity and the interaction with the proposed target, we used quantitative multiparameter immunofluorescence assays to measure mitotic arrest and nuclear morphology in conjunction with *in vitro* tubulin assembly and displacement studies using the potent taxoid site binding agent epothilone B. Quantitative structure-activity relationship (QSAR) analyses were then employed to correlate the structures with cytotoxic effects.




Fig. 1. Structures of (–)-dictyostatin and (+)-discodermolide, their analogs used in these studies, and those of paclitaxel and epothilone B.

## Materials and Methods

**Materials.** Dictyostatin was synthesized as described previously (Shin et al., 2004). The syntheses of the analogs are reported elsewhere (Shin et al., 2005, 2007; Fukui et al., 2006; Jung et al., 2007). Tubulin was isolated to electrophoretic homogeneity from fresh bovine brain (Hamel and Lin, 1984). Paclitaxel was obtained from the Drug Synthesis and Chemistry Branch, National Cancer Institute (Bethesda, MD). Discodermolide, epothilone B, and [ $^{14}\text{C}$ ]epothilone B (specific activity, 111 mCi/mmol) were generous gifts from Novartis Pharma AG (Basel, Switzerland). Rabbit anti-phosphohistone H3 antibody was purchased from Upstate Cell Signaling (Billerica, MA). Cy3-labeled donkey anti-rabbit and fluorescein-5-isothiocyanate (FITC)-labeled anti-mouse secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). GTP and 2',3'-dideoxy-GTP (ddGTP) were purchased from U.S. Biochemical Corp. (Cleveland, OH). All other chemicals including mouse anti- $\alpha$ -tubulin antibody were purchased from Sigma (St. Louis, MO).

## Methods

**High-Content Analysis of Mitotic Arrest.** Detailed conditions for the high-content analysis of microtubule stabilizers using a cell-based immunofluorescence assay have been described previously (Mínguez et al., 2003). In brief, HeLa cells were plated at a cell density of 8000 cells per well in collagen-1-coated 384-well microplates. Cells were allowed to attach and spread for 3 to 8 h and treated with either vehicle (DMSO) or 10 2-fold concentration gradients of test agents and incubated for an additional 20 h at 37 °C. After the incubation, cells were fixed with formaldehyde containing 10  $\mu\text{g}/\text{ml}$  Hoechst 33342 to stain nuclei/chromatin, permeabilized with Triton X-100 and simultaneously immunostained with antibodies against  $\alpha$ -tubulin (mouse monoclonal, 1:2500 dilution; Sigma, St. Louis, MO) and phosphohistone H3 (rabbit polyclonal, 1:1000 dilution; Upstate) followed by FITC-labeled donkey anti-mouse IgG (1:250) and Cy3-labeled donkey anti-rabbit IgG (1:250) (both from Jackson ImmunoResearch Laboratories). Each well was imaged on an ArrayScanII (Cellomics Inc., Pittsburgh, PA) using an Omega XF93 filter set at excitation/emission wavelengths of 350/461 nm (Hoechst), 494/519 nm (FITC), and 556/573 nm (Cy3). Images were analyzed with the Target Activation Bioapplication (Cellomics, Inc.). The algorithm provided quantitative measurements of nuclear FITC and Cy3 intensity, cell density, and mean and total nuclear Hoechst 33342 intensities. Microtubule mass was defined as the average FITC intensity in an area defined by the Hoechst-stained nuclei. To estimate the percentage of cells with elevated phosphohistone H3 levels and with condensed chromatin, thresholds were defined as the average intensity plus 1 S.D. of Hoechst or Cy3 intensities in anti-phosphohistone H3- or Hoechst 33342-stained cells, respectively, using a minimum of 1000 vehicle-treated cells per well. Cells were classified as positive if their average intensities in the Hoechst or Cy3 channel exceeded these thresholds. Cell density was defined as the number of nuclei per imaging field. The  $\text{EC}_{50}$  was the effective concentration of drug that decreased cell density by 50% compared with vehicle-treated control.

**Tubulin Assembly in Vitro.** Tubulin assembly was monitored by turbidity development at 350 nm as described previously (Madiraju et al., 2005). Reaction mixtures (final volume, 0.25 ml) contained tubulin (1 mg/ml; 10  $\mu\text{M}$ ), monosodium glutamate (MSG; 0.8 M from a stock solution adjusted to pH 6.6 with HCl), DMSO [final volume, 4% (v/v)], and test agent (10  $\mu\text{M}$ ). Reaction mixtures without test agent were cooled to 0°C and added to quartz cuvettes held at 0.25–0.5°C a temperature-controlled (via a Peltier unit), six-sample spectrophotometer (DU 7400; Beckman Coulter, Fullerton, CA). Test agent in DMSO was then rapidly mixed into the reaction mixture. Absorbance at 350 nm was monitored in each cuvette every 15 s. Each six-sample run contained one positive control (paclitaxel, 10  $\mu\text{M}$  final concentration) and one negative control (DMSO only). Baselines were established at 0.25–2.5°C. The temperature was rapidly raised to 30°C (in approximately 1 min) and held there for 20 min. The temperature was then rapidly lowered back to 0.25–2.5°C. The change in absorbance 20 min after

samples reached 30°C was used to calculate the extent of polymerization. The change in absorbance at 21 min in the paclitaxel sample was assigned as 100% assembly (positive control), whereas the change in absorbance in the DMSO-only sample (negative control) was assigned as 0% assembly.

**Radioligand Displacement Studies.** Determination of the equilibrium binding constant ( $K_d$ ) for epothilone B was determined using methods described previously (Madiraju et al., 2005). An 80  $\mu\text{M}$  stock solution of [ $^{14}\text{C}$ ]epothilone B was prepared in 50% DMSO. Samples of [ $^{14}\text{C}$ ]epothilone B at 0.005 to 2  $\mu\text{M}$  were prepared in 4:1 (v/v) 0.75 M MSG/DMSO (total volume, 50  $\mu\text{l}$ ) and warmed to 37°C. Microtubules were preformed in separate tubes by incubating 2.5  $\mu\text{M}$  tubulin and 25  $\mu\text{M}$  ddGTP in 0.75 M MSG/DMSO for 30 min at 37°C. Equal volumes (50  $\mu\text{l}$  each) of the radiolabeled compound mixtures and microtubule solutions were mixed and incubated for 30 min at 37°C. Reaction mixtures were then centrifuged in an Allegra TM 64R (Beckman-Coulter, Fullerton, CA) at 14,000 rpm for 30 min at room temperature. The amount of radiolabel in the supernatant was determined by scintillation spectrometry in a multipurpose scintillation counter (LS6500; Beckman-Coulter). Nonspecific radiolabel binding was determined from competition experiments with 8  $\mu\text{M}$  discodermolide and processing as described above.

Inhibitors in 4:1 (v/v) 0.75 M MSG/DMSO were preincubated with radiolabeled compound in a final volume of 50  $\mu\text{l}$  for 10 min at 37°C. To this mixture, 50  $\mu\text{l}$  of microtubules that were formed as described above were added, and the resulting mixture was incubated for 30 min at 37°C. Reaction mixtures were centrifuged as described above, and a 50- $\mu\text{l}$  aliquot of supernatant was analyzed by scintillation spectrometry.

Saturation binding data for [ $^{14}\text{C}$ ]epothilone B were analyzed using a modified version of Swillens' equation that accounts for ligand depletion (Swillens, 1995; Motulsky and Christopoulos, 2003):

$$\text{Total Binding} = \{(B_{\max} \times ([L]_T - [L]_B)) /$$

$$(K_D + (([L]_T - [L]_B))) + ([L]_T - [L]_B) \times NS \quad (1)$$

where  $B_{\max}$  is the number of binding sites,  $[L]_T$  is the amount of radioligand added,  $[L]_B$  is the amount of ligand bound to tubulin polymer, and  $NS$  is the fraction of radioligand bound to nonspecific sites. Nonlinear regression analysis was performed using Prism software (GraphPad Software, San Diego, CA), which allows for the simultaneous fitting of nonspecific and total binding data.

The equilibrium inhibition constant ( $K_i$ ) values for dictyostatin and its analogs were determined using a modified Hanes analysis (Edler et al., 2005):

$$[S]/\nu = K'_d \times (1 + [I]/K_i) + [S] \quad (2)$$

where  $[S]$  is the free concentration of [ $^{14}\text{C}$ ]epothilone B, and  $\nu$  is the fractional saturation of microtubule sites by epothilone B and inhibitor. GraphPad Prism was used for linear regression, providing the  $-K_d$  value as the x-intercept in the absence of inhibitor. The x-intercept in the presence of inhibitor,  $-K_d(1 + [I]/K_i)$ , was used to calculate the  $K_i$  values.

**QSAR.** Molecular modeling and QSAR analyses were performed with the Cerius<sup>2</sup> suite of programs (v. 4.5; Accelrys, Inc., San Diego, CA) using the Merck Molecular Force Field/CHARMM, the adopted-basis Newton-Raphson approach to molecular mechanics minimizations in a dielectric field = 1, rigid body superimpositions based on atom similarities, the MOPAC93 suite of semiempirical molecular orbital algorithms, and the genetic function approximation as described previously (Verdier-Pinard et al., 1998).

## Results

**Cellular Effects of Dictyostatin and Its Analogs Determined By Multiparameter Immunofluorescence Microscopy.** We have reported previously the use of multipa-



parameter high-content analyses, a tool to acquire, manage, and retrieve information from multiparametric experiments to yield information about the activity and spatial regulation of multiple targets in individual cells (Giuliano et al., 1997), to characterize the responses of tumor cells to MT-stabilizing agents (Mínguez et al., 2003; Madiraju et al., 2005). This assay provides information on the effects of such agents on MT mass, histone H3 phosphorylation, nuclear morphology, and cytotoxicity. HeLa cells were grown in 384-well microtiter plates and treated with each compound for 21 h. The cells were fixed and their nuclei stained with Hoechst 33342. They were then permeabilized, MTs and phosphohistone H3 were immunostained, and FITC- and Cy3-conjugated secondary antibodies were added. From Hoechst staining, a nuclear mask was generated defining the area used to determine MT mass and percentage of histone H3 phosphorylation. MT mass was determined from the cells' average nuclear FITC intensity. Histone H3 phosphorylation was determined from the number of cells with a higher pixel intensity for Cy3 than the average plus 1 S.D. seen within vehicle-treated cells. Using a range of concentration of test agents, the minimum detectable effective concentration (MDEC) was determined. The MDEC value is the minimum concentration at which each agent causes a response in excess of vehicle-treated control cells (Mínguez et al., 2003). The MDECs for nuclear condensation, histone H3 phosphorylation, and changes in MT morphology for dictyostatin and its analogs are shown in Table 1. For toxicity determinations, cell densities were measured as the number of Hoechst 33342-stained nuclei per imaging field. The toxicity measurements in HeLa cells were consistent with those reported for other human cancer cell lines, where the toxicity measure used was a decrease in absorbance at 490 nm after cells treated with drug were exposed to 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and *N*-methylphenazine methylsulfate (Jung et al., 2007; Shin et al., 2007). Toxicity measurements and the MDEC values generated from this initial screen provided a rapid and economical assessment of the analogs' biological activities. As shown in Table 1, the 20-membered ring iso analogs of dictyostatin, 16-*epi*-isodictyostatin, 15Z,16-normethylisodictyostatin, and 16-*epi*-dictyostatin were inactive, yielding MDEC and EC<sub>50</sub> values >5 μM. This led to the conclusions that the 22-membered ring of dictyostatin is essential for retention of biological activity and that if

the C16 methyl group is present, it must be in the *S* configuration (Jung et al., 2007). 2*E*,15*Z*,16-Normethyl-dictyostatin analog was considerably less active than 15*Z*,16-normethyldictyostatin, proving that C2:3*Z* geometry is necessary for activity. From these data, the four most potent analogs were chosen for further evaluation: 6-*epi*-dictyostatin, 7-*epi*-dictyostatin, 16-normethyldictyostatin, and 15*Z*,16-normethyldictyostatin.

Figure 2 illustrates the cellular phenotype observed after treatment with the four test agents. MTs in cells treated with vehicle (A) were well organized, and the few cells undergoing mitosis showed normal spindle formation. Cells treated with dictyostatin (B) showed MT bundling and abnormal spindle formation, characteristic of cells treated with an MT stabilizer. Figure 2, C–F, represents the images obtained when HeLa cells were treated with the indicated concentrations of 6-*epi*-dictyostatin, 7-*epi*-dictyostatin, 15*Z*,16-normethyldictyostatin, or 16-normethyldictyostatin, respectively. All compounds produced morphological changes in the cells similar to those of dictyostatin, including MT bundling and abnormal spindles. Quantitative analysis showed that all compounds increased mitotic indices, nuclear condensation, MT mass, and a loss of cell density at nanomolar concentrations. 6-*epi*-Dictyostatin and 7-*epi*-dictyostatin affected all parameters at concentrations comparable with dictyostatin, whereas the 16-normethyl derivatives seemed to have lost some activity. We were surprised to find that 15*Z*,16-normethyldictyostatin was more potent in all aspects than 16-normethyldictyostatin, which was the least potent agent. Thus, high-content analysis provided a rapid and efficient means to generate cellular SAR data on mitotic arrest, microtubule morphology, and cytotoxicity. It demonstrated that the structural modifications made in the 6, 7, 15, and 16 positions did not significantly reduce compound activity in cells.

**Determination of the Ability of Dictyostatin and Its Analogs to Induce Tubulin Assembly and Form Cold Stable Polymer.** We previously reported that 16-normethyldictyostatin retains the ability to induce tubulin polymerization in the absence of GTP (Jung et al., 2007). To assess the hypernucleating ability of the dictyostatin epimers and olefin, we performed in vitro tubulin assembly assays under conditions in which polymerization does not occur in the absence of test agents and compared the analogs' activities with that of paclitaxel. Isolated tubulin was cooled to 2.5°C,


TABLE 1

Potencies of dictyostatin and its analogs in HeLa cells using multiparameter fluorescence microscopy

Data are average of at least three independent experiments ± S.D. The mitotic index is the percentage of phosphohistone H3-positive cells

Compound	EC <sub>50</sub>		MDEC	
	Cell Density	Nuclear Condensation	Mitotic Index	Microtubule Mass
	nM		nM	
Paclitaxel	10.4 ± 1.9	3.9 ± 2.0	3.5 ± 1.2	5.2 ± 0.4
Dictyostatin	9.2 ± 6.6	3.9 ± 1.0	5.8 ± 1.5	5.4 ± 1.9
16- <i>epi</i> -Dictyostatin	1872 ± 449	1132 ± 66	1032 ± 173	1278 ± 181
16- <i>epi</i> - <i>seco</i> -Dictyostatin methyl ester	>5000	>5000	>5000	>5000
16- <i>epi</i> -Isodictyostatin	>5000	>5000	>5000	>5000
16-Normethyldictyostatin	34.7 ± 6.2	23.7 ± 8.8	24.1 ± 5.4	25.0 ± 9.0
7- <i>epi</i> -Dictyostatin	17.5 ± 1.9	7.7 ± 2.1	8.5 ± 3.9	8.0 ± 3.2
6- <i>epi</i> -Dictyostatin	8.9 ± 2.7	4.5 ± 1.9	3.8 ± 2.8	4.0 ± 0.9
2 <i>E</i> ,15 <i>Z</i> ,16-Normethyldictyostatin	896 ± 135	738 ± 214	520 ± 95	647 ± 106
15 <i>Z</i> ,16-Normethyldictyostatin	23.9 ± 15.5	12.6 ± 5.2	9.3 ± 0.2	11.7 ± 1.7
9- <i>epi</i> -15 <i>Z</i> ,16-Normethyldictyostatin	>5000	>5000	>5000	>5000
15 <i>Z</i> ,16-Normethylisodictyostatin	>5000	>5000	>5000	>5000

and test agents were added to a final concentration of 10  $\mu\text{M}$ . The test agent-containing tubulin solutions were rapidly warmed to 30°C to induce assembly, and after 20 min at 30°C, the temperature was lowered to 0°C to test the cold stability of the polymer induced by the agents. Figure 3 shows that three agents were more active than the positive control (paclitaxel). Dictyostatin was the most potent compound in terms of nucleating and polymerizing ability, closely followed by 7-*epi*-dictyostatin and 6-*epi*-dictyostatin. There were some slight differences between the C6- and C7-epimers. 7-*epi*-Dictyostatin induced polymer formation more rapidly than did 6-*epi*-dictyostatin, but the extent of polymerization caused by 6-*epi*-dictyostatin was greater. The polymer formed with 6-*epi*-dictyostatin seemed more stable




**Fig. 2.** Immunofluorescence images of HeLa cells treated with dictyostatin and analogs. HeLa cells were treated with vehicle (DMSO) or with test agents for 20h followed by simultaneous immunostaining of  $\alpha$ -tubulin (green), phosphohistone H3 (red), and nuclei (blue). A, vehicle control. B, dictyostatin (31 nM). C, 6-*epi*-dictyostatin (7.8 nM). D, 7-*epi*-dictyostatin (15.6 nM). E, 15Z,16-normethyldictyostatin (19.5 nM). F, 16-normethyldictyostatin (31 nM). Vehicle-treated cells have highly organized microtubules and a low percentage of mitotic cells. All compounds tested caused a heterogenous response of tubulin disorganization, increased numbers of phosphohistone H3-positive cells, enhanced chromatin condensation, and nuclear fragmentation. Images shown are representative of a single experiment that was repeated twice with each experiment yielding similar results.

against cold-induced depolymerization than the polymer from 7-*epi*-dictyostatin or dictyostatin itself. The nucleating and polymerizing activities of 15Z,16-normethyldictyostatin and 16-normethyldictyostatin were reduced but still comparable with those of paclitaxel. Polymer induced by these two compounds was cold-stable.

**Characterization of [ $^{14}\text{C}$ ]Epothilone B Saturation Binding to Microtubules.** We previously showed that dictyostatin and the four analogs have the ability to compete with radiolabeled paclitaxel for binding to preformed MTs in vitro (Madiraju et al., 2005; Jung et al., 2007). Here, we expanded on these preliminary observations by performing detailed binding kinetics using [ $^{14}\text{C}$ ]epothilone B. Epothilone B has an even higher affinity to the taxoid site on tubulin than paclitaxel (Kowalski et al., 1997b). Because the saturation binding kinetics of [ $^{14}\text{C}$ ]epothilone B have not been reported, we first determined its  $K_d$  value for the binding to MTs. Fig. 4, top, shows the extent of nonspecific binding of [ $^{14}\text{C}$ ]epothilone B bound to MTs in the presence and absence of 8  $\mu\text{M}$  discodermolide. Fitting the data using Swillens' modified equation (eq. 1), which simultaneously fits total binding and nonspecific binding, and accounts for ligand depletion, yielded a  $K_d$  value for epothilone B of  $36.04 \pm 1.58$  nM. Because the  $K_d$  value of paclitaxel is reported to be between 0.06 and 0.1  $\mu\text{M}$  and because the relative affinities of agents for the taxoid site followed the order paclitaxel < epothilone B < discodermolide, the  $K_d$  value obtained in these experiments for epothilone B was considered reasonable and acceptable (Buey et al., 2004).

**Determination of Inhibition Constants for Dictyostatin and Its Analogs using [ $^{14}\text{C}$ ]Epothilone B in Competition Experiments.** To determine the  $K_i$  values for dictyostatin and its analogs, a modified Hanes analysis method (eq. 2) was employed (Edler et al., 2005). The method uses the free concentration of radioligand instead of the total concentration and accounts for the free inhib-



**Fig. 3.** Tubulin polymerization assay to determine effects of dictyostatin and its analogs on tubulin assembly. The reaction mixture contained 4% DMSO, 10  $\mu\text{M}$  test agent, 10  $\mu\text{M}$  bovine brain tubulin, and 0.75 M MSG, pH 6.6. DMSO was the negative control and paclitaxel the positive control. All components except for test agents were cooled to 2.5°C, and test agents were added to cuvettes containing the reaction mixtures in a temperature-controlled spectrophotometer. One min after compound addition, the reaction mixtures were warmed to 30°C. After 20 min at 30°C, the reaction temperature was again dropped to 2.5°C to determine the cold stability of polymer formed.  $\circ$ , 4% DMSO;  $\square$ , (–)-dictyostatin;  $\blacktriangledown$ , 16-normethyldictyostatin;  $\times$ , 15Z,16-normethyldictyostatin;  $\blacklozenge$ , 6-*epi*-dictyostatin;  $*$ , 7-*epi*-dictyostatin;  $\triangle$ , paclitaxel.




itor concentrations. As shown in Fig. 4, bottom, plots of free concentration of [ $^{14}$ C]epothilone B versus free substrate ( $S$ ) divided by the fractional saturation ( $\nu$ ; used instead of enzyme velocity) for 6-*epi*-dictyostatin yielded plots of parallel lines with slopes close to 1. The  $K_d$  value for [ $^{14}$ C]epothilone B, determined from the negative intercept on the  $x$ -axis, was  $50 \pm 20$  nM, close to the value obtained from the saturation experiments in Fig. 4, top. As shown in Table 2, 16-normethyldictyostatin and 15Z,16-normethyldictyostatin gave the highest  $K_i$  values, reflecting their reduced binding affinity. The  $K_i$  value for 15Z,16-normethyldictyostatin was  $4.47 \pm 0.28$   $\mu$ M, and the value for 16-normethyldictyostatin was  $4.55 \pm 0.41$   $\mu$ M. These

data correlated with the tubulin polymerization data, which showed that 16-normethyldictyostatin and 15Z,16-normethyldictyostatin were the least potent of the compounds in nucleation and MT stabilization experiments (Fig. 3). Dictyostatin showed the highest affinity for the taxoid site, with a  $K_i$  value of  $70 \pm 20$  nM. Based on their effects on MT assembly, it was surprising to find that 6-*epi*-dictyostatin and 7-*epi*-dictyostatin had substantially less affinity under the conditions of the competition experiments, yielding  $K_i$  values of  $480 \pm 70$  and  $930 \pm 310$  nM, respectively.

**QSAR Analyses.** Using the NMR-derived solution structure of discodermolide as a template (Smith et al., 2001), molecular models of dictyostatin, its analogs, discodermolide, and 14-normethyldiscodermolide were built. The lowest energy conformers of the models were found by exhaustive molecular mechanics minimization, and then all models were superimposed onto that of discodermolide. The only structures that did not superimpose well were 2E,15Z,16-normethyldictyostatin and the 20-member iso analogs. A large number of thermodynamic, electronic, steric, and linear free-energy descriptors were then calculated for each model.

At this point we needed to decide upon the biological metric to use for the “activity” portion of the QSAR. We chose the 50% growth inhibitory concentrations ( $GI_{50}$ ) of the compounds against human ovarian carcinoma 1A9 cells, which express wild type  $\beta$ -tubulins. Because the number of descriptors far exceeded the number of compounds studied, the genetic function approximation (GFA) was used to fit the data to the smallest possible number of descriptors. In the GFA approach, a random population of equations is generated, their fitness is determined by a number of statistical metrics (in particular Friedman’s lack-of-fit score and  $R^2$ ), and then the equations are “evolved” by inclusion of combinations (child) from two of the best equations (parents) (Verdier-Pinard et al., 1998). This process is reiterated (each iteration is termed a “generation”), with a given frequency of “mutation” (random descriptor loss or use) incorporated into each iteration until the best descriptors and QSAR equations are found. The five best equations (according to statistical metrics) from 100,000 generations were:

$$\begin{aligned}
 -(\log GI_{50}) = & -0.017328 - 0.41287 (\text{rotatable bonds}) \\
 & + 0.091723(HF\_MOPAC) - 0.223325(HF) \\
 & + 0.0611096 (\text{dipole\_MAG}) \quad (3)
 \end{aligned}$$



**Fig. 4.** Top, saturation binding data for the binding of [ $^{14}$ C]epothilone B to microtubules. Isolated tubulin was incubated with [ $^{14}$ C]epothilone B, and the amount of protein-bound radioactivity was quantified as described under *Materials and Methods* section. The  $x$ -axis shows the total [ $^{14}$ C]epothilone B added, and the  $y$ -axis shows the amount of ligand bound ( $\blacksquare$ ). Nine concentrations in the range of 5 nM to 2  $\mu$ M radiolabeled epothilone B ( $\blacksquare$ ) were used to determine the equilibrium binding constant ( $36.04 \pm 1.58$  nM). Nonspecific binding was determined by competition with 8  $\mu$ M discodermolide ( $\blacktriangle$ ). Each data point is the mean of three independent experiments  $\pm$  S.D. Bottom, Hanes plot of the inhibition of binding of [ $^{14}$ C]epothilone B to microtubules by 6-*epi*-dictyostatin. The  $y$ -axis is free substrate concentration (micromolar)/fractional saturation ( $S/\nu$ ). All experiments yielded parallel lines with a slope of  $\sim 1$ . The  $x$ -axis is free concentration of [ $^{14}$ C]epothilone B (micromolar). The fractional saturation was calculated from the total amount of tracer added minus the free concentration of tracer counted. Experiments were performed as described under *Materials and Methods* section.  $K_i$  values were determined from the  $x$ -intercept, equal to  $-(K_d(1 + [I]/K_i))$ .  $\blacksquare$ , no inhibitor;  $\blacktriangledown$ ,  $\blacktriangle$ , and  $\blacklozenge$ , 6-*epi*-dictyostatin at 1.6, 0.8, and 0.3  $\mu$ M, respectively.

**TABLE 2**

Equilibrium inhibition constants for dictyostatin and its analogs calculated from Hanes analysis of [ $^{14}$ C]epothilone B competition experiments

Concentrations used ranged from 0.25 to 12  $\mu$ M for the inhibitors dictyostatin, 6-*epi*-dictyostatin, and 7-*epi*-dictyostatin. For the less potent inhibitors, concentrations used ranged from 1 to 50  $\mu$ M. [ $^{14}$ C]epothilone B concentrations were 1, 2, 2.5, and 3  $\mu$ M for all experiments. Free inhibitor concentration was calculated by subtracting the amount of tracer displaced by the inhibitor from the total amount of inhibitor added.

Compound	$K_i$ $\mu$ M
15Z,16-Normethyldictyostatin	$4.47 \pm 0.28$
16-Normethyldictyostatin	$4.55 \pm 0.41$
6- <i>epi</i> -Dictyostatin	$0.48 \pm 0.07$
7- <i>epi</i> -Dictyostatin	$0.93 \pm 0.31$
Dictyostatin	$0.07 \pm 0.02$

$$\begin{aligned}
 -(\log \text{GI}_{50}) = & -26.5019 + 0.03692 (\text{area}) \\
 & - 0.328785 (\text{rotatable bonds}) - 0.04374 (\text{HF}) \\
 & + 0.924229 (\text{dipole\_MOPAC}) \quad (4)
 \end{aligned}$$

$$\begin{aligned}
 -(\log \text{GI}_{50}) = & -26.3842 + 0.1088 (\text{area}) \\
 & + 1.31599 (\text{dipole\_MOPAC}) - 0.353032 (\text{MR}) \\
 & + 0.654779 (\log P) \quad (5)
 \end{aligned}$$


$$\begin{aligned}
 -(\log \text{GI}_{50}) = & 1.694349 - 0.305704 (\text{rotatable bonds}) \\
 & - 0.135425 (\text{HF}) + 0.605182 (\text{dipole\_MOPAC}) \\
 & - 0.053736 (\text{HF\_MOPAC}) \quad (6)
 \end{aligned}$$

$$\begin{aligned}
 -(\log \text{GI}_{50}) = & -48.6935 + 0.200571 (\text{MR}) \\
 & - 0.270041 (\text{rotatable bonds}) + 1.27617 (\text{dipole\_MOPAC}) \\
 & + 0.117247 (\text{area}) \quad (7)
 \end{aligned}$$

where *rotatable bonds* is the number of single bonds contained within the molecule, *HF* is the heat of formation (the change in enthalpy for forming a molecule from its constituent atoms) calculated with MNDO or with PM3 in MOPAC, *logP* is the calculated octanol-water partition coefficient, *MR* is molar refractivity, *area* describes the Van der Waals area of a molecule, and the *dipole* terms are the indicated vector within or a sum of all the vectors describing the dipole moment of the molecule.

To determine the most significant descriptors in each equation, a "leave-one-(descriptor)-out" exercise was performed. This entailed calculating the activity with one of the descriptors set to zero and then the deviation of the resulting value from the predicted activity when all descriptors were used. For eqs. 4, 5, and 7, the most important contributors to activity were area and molar refractivity. For eqs. 3 and 6, the most important descriptor was the heat of formation.

The predicted activity values generated from these equations were plotted versus the actual activity in the 1A9 cells



**Fig. 5.** Graph of the  $-\log$  (molar) predicted versus  $-\log$  (molar) actual antiproliferative activities of dictyostatin, discodermolide, and the 12 analogs of dictyostatin and 14-normethyldictyostatin in 1A9 human ovarian cancer cells. Predicted values were calculated from eq. 1 (see *Materials and Methods*) in the Cerius<sup>2</sup> suite of programs using the genetic function approximation approach. The  $R^2$  was for this equation was 0.943.

to determine correlations. As shown in Fig. 5, plotting of the  $-\log$  molar predicted values generated from eq. 3 versus the  $-\log$  molar actual values led to an  $R^2$  of 0.943. Values for  $R^2$  of the other four equations were also  $>0.93$ .

## Discussion

A multiparameter fluorescence-based cellular assay was used as an initial screen of dictyostatin and its analogs. Several conclusions were reached about the SAR for dictyostatin based on the compounds' effects on HeLa cell proliferation, histone H3 phosphorylation, MT mass, and nuclear morphology. The importance of a 22-membered ring was proven by the inactivity of the 20-membered analogs 16-*epi*-isodictyostatin and 15Z,16-normethylisodictyostatin. If the C16 methyl group is present, it must be in the *S*-configuration, which is seen by the complete loss in activity of the 16-*epi*-dictyostatin analog. C2:3Z geometry is also necessary. The most potent analogs from this initial screen were 6-*epi*-dictyostatin, 7-*epi*-dictyostatin, 16-normethyldictyostatin, and 15Z,16-normethyldictyostatin. Only minor differences in these four compounds' cellular activities were observed, although 6-*epi*-dictyostatin and the parent compound were the most active agents in all experiments. This is consistent with data from antiproliferative assays with 1A9 human ovarian cancer cells, where all of these analogs were shown to be potent inhibitors of cell proliferation with  $\text{IC}_{50}$  values in the low nanomolar range (Jung et al., 2007).

Although, qualitatively, the rank order of cellular activities correlated with the in vitro activities, there were some differences in the compounds' abilities to cause in vitro tubulin assembly and in the binding site affinity studies. It is noteworthy that the 16-normethyl derivatives 15Z,16-normethyldictyostatin and 16-normethyldictyostatin had almost 5-fold higher  $K_i$  values compared with the C6- and C7-epimers. This is consistent with the hypothesis that the C16 methyl group is important in binding to the taxoid site through a key interaction with Phe270 on  $\beta$ -tubulin. Our recent report shows that 16-normethyldictyostatin has decreased potency in the paclitaxel-resistant 1A9/PTX10 ovarian cancer cell line, which has a Phe270-to-Val point mutation in the taxoid binding site (Giannakakou et al., 1997; Shin et al., 2005). This is in agreement with our present results, where the lower affinity observed in competition experiments with 15Z,16-normethyldictyostatin and 16-normethyldictyostatin can be attributed to the loss of the favorable interaction of the C16 methyl group of dictyostatin with Phe270 in  $\beta$ -tubulin.

As observed from a similar loss in potency in the 1A9/PTX10 line, the interaction between the benzoyloxy group of paclitaxel and Phe270 of  $\beta$ -tubulin is important for paclitaxel's activity (Giannakakou et al., 1997). The importance of the interaction between Phe270 and methyl substituents in dictyostatin, epothilone B, and discodermolide is now becoming well established. Molecular modeling studies have suggested that the C14 methyl group of discodermolide is positioned in a favorable interaction with Phe270 in the hydrophobic binding pocket of the taxoid site (Xia et al., 2006). The importance of this interaction has been confirmed by the decrease of nucleating ability of 14-normethyldiscodermolide in tubulin polymerization assays (Smith et al., 2005). A two-dimensional NMR-derived binding model of epothilone A to the tubulin heterodimer suggests that the increased potency of

epothilone B over epothilone A is due to the interaction of the C12 methyl with Phe270 (Reese et al., 2007).

As shown by our QSAR studies, the size of the molecule (area and molar refractivity) is the most significant contributor to cytostatic activity against 1A9 ovarian cancer cells. A loss of a methyl substituent would certainly lead to a decrease in the van der Waals surface area of the molecule and, according to our calculations, leads to a decrease in activity. Molar refractivity is a measure of the volume occupied by the molecule. It is dependent on a number of factors, such as molecular weight, refractive index, and density. This descriptor relates to the London dispersive forces that act in the drug-receptor interactions (Padron et al., 2002). Again, 16-normethyldictyostatin and 15Z,16-normethyldictyostatin would be expected to have molar refractivities differing from those of dictyostatin and its C6 epimer, whose molar refractivities are identical.

Changes to the C6 and C7 stereocenters of dictyostatin were explored because they are present in the structure of discodermolide as its C4 and C5 carbons, part of its delta lactone ring. The multiparameter immunofluorescence studies with 6-*epi*-dictyostatin and 7-*epi*-dictyostatin showed that these analogs produced MT bundling and abnormal spindle formation at nanomolar concentrations. Their ability to produce these various cellular responses was observed at lower concentrations than required with dictyostatin. Although there was a slight loss in nucleation ability in tubulin polymerization assays, these compounds retained their ability to induce assembly of microtubules and to form cold-stable polymer. In addition, both compounds still had a high affinity for the taxoid site on  $\beta$ -tubulin, with the  $K_i$  values determined in competition experiments with [ $^{14}$ C]epothilone B of 480 and 930 nM for 6-*epi*-dictyostatin and 7-*epi*-dictyostatin, respectively. From these experiments it can be said that single stereochemical changes to this area are not only well tolerated but also lead to no loss in potency in vivo.

The saturation binding kinetics of epothilone B were characterized. One of the fundamental assumptions of equilibrium binding is that only a small amount of substrate binds to its target, leaving the relative amount of free substrate concentration unchanged. Ligand depletion occurs if more than 10% of the substrate binds to the protein (Motulsky and Christopoulos, 2003). When ligand depletion occurs, this assumption is invalidated and can, if not taken into account, cause errors in data analysis (Morton et al., 2002; Carter et al., 2007). This problem is commonly encountered in the centrifuge-based assay used to determine the kinetics of MT stabilizing agents. For this reason, the saturation binding data were analyzed using the modified Swillens' equation (eq. 1), which not only accounts for ligand depletion but also fits total binding and nonspecific binding simultaneously. Fitting the nonspecific and total binding data simultaneously allows for the calculation of free ligand, and defines nonspecific binding as a constant fraction of the free ligand concentration. The  $K_d$  value obtained using this analysis was reasonable as a measure of the affinity of epothilone B for the taxoid site in comparison to results from previous competitive inhibition studies (Kowalski et al., 1997; Madiraju et al., 2005).

The binding kinetics of dictyostatin and its analogs were determined with radiolabeled epothilone B. Epothilones are competitive inhibitors of paclitaxel binding, and the epothi-

lones retain activity against almost all known paclitaxel-resistant cell lines (Kowalski et al., 1997); the exception is the 1A9/A8 line, which possess a mutation of Arg282->Gln in  $\beta$ -tubulin and is resistant to both paclitaxel and epothilone B (Giannakakou et al., 2000). All of the agents tested here were found to be competitive inhibitors of the binding of epothilone B to tubulin polymer, implying that dictyostatin and epothilone B share a common binding site on MTs. As in the saturation binding experiments with [ $^{14}$ C]epothilone B, significant ligand depletion was observed in the competition experiments. For analysis of competition experiments with ligand depletion, it would be correct to assume that the inhibitor concentration would be depleted as well as substrate concentration. The modified Hanes analysis (eq. 2) used by Edler et al. (2005) and employed here accounts for the free concentration of radiolabeled tracer and that of the free inhibitor.

In conclusion, a number of potent analogs of the microtubule stabilizer dictyostatin have been tested to determine the cellular responses they evoke, their effects on tubulin polymerization, and their ability to inhibit binding of [ $^{14}$ C]epothilone B to MTs. During this process, the saturation binding kinetics of epothilone B was characterized, and epothilone B demonstrated great affinity for the taxoid site. Dictyostatin and its analogs are all competitive inhibitors of [ $^{14}$ C]epothilone B binding as demonstrated by Hanes analysis. These experiments have further led to the conclusion that dictyostatin, discodermolide, epothilone B, and paclitaxel have favorable interactions with Phe270 within the taxoid binding site on  $\beta$ -tubulin. A change to the configuration of the stereocenter at C6 or C7 of dictyostatin is well tolerated. From this work, it can be conjectured that for good efficacy against cancer cell lines, all future analogs of dictyostatin must retain the ability to interact with Phe270 on  $\beta$ -tubulin, and that this interaction is important to the efficacy of many other taxoid site-binding, MT-stabilizing compounds. The characterization of the 6-*epi*-dictyostatin analog as a potent MT-stabilizing agent has motivated the gram scale synthesis for use in preclinical studies. Our QSAR analyses led to a number of equations that will be useful in guiding the production of and predicting the cellular activity of new, more potent dictyostatin analogs. The four descriptors employed in these equations are all variables that can easily be manipulated by a medicinal chemist.

#### Acknowledgments

We thank Drs. Markus Wartmann, Paul McSheehy, and Kenneth Bair and Fred Kinder of Novartis Pharma for the generous gifts of, respectively, [ $^{14}$ C]epothilone B, epothilone B, and discodermolide. We also thank Prof. Amos B. Smith III (University of Pennsylvania, Philadelphia, PA) for the gift of 14-normethyldiscodermolide, and Prof. Galina Kirilova for the use of her equipment and lab space.

#### References

- Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E and Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. *Cancer Res* 55:2325–2333.
- Buey RM, Diaz F, Andreu JM, O'Brate A, Giannakakou P, Nicolau KC, Samai PK, Ritzen A, and Namato K (2004) Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. *Chem Biol* 11:225–236.
- Carter CM, Leighton-Davies JR, and Charlton SJ (2007) Miniaturized receptor binding assays: Complications arising from ligand depletion. *J Biomol Screen* 12:255–266.
- Edler MC, Buey RM, Gussio R, Marcus AI, Vanderwal CD, Sorensen EJ, Diaz JF, Giannakakou P, and Hamel E (2005) Cyclostreptin (FR182877), an antitumor



- tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site. *Biochemistry* **44**:11525–11538.
- Fukui Y, Brückner AM, Shin Y, Balachandran R, Day BW, and Curran DP (2006) Fluorous mixture synthesis of (–)-dictyostatin and three stereoisomers. *Org Lett* **8**:301–304.
- Gaitanos TN, Buey RM, Diaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, and Miller JH (2004) Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. *Cancer Res* **64**:5063–5067.
- Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, and Porchinsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant  $\beta$ -tubulins that exhibit impaired paclitaxel-driven polymerization. *J Biol Chem* **272**:17118–17125.
- Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, and Fojo T (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. *Proc Natl Acad Sci U S A* **97**:2904–2909.
- Giuliano KA, DeBiasio RL, Dunlay T, Gough A, Volosky JM, Zock J, Pavlakis GN, and Taylor DL (1997) High-content screening: a new approach to easing key bottlenecks in the drug discovery process. *J Biomol Screen* **2**:249–259.
- Gunasekera SP, Gunasekera M, Longley RE, and Schulte GK (1990) Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge *Discodermia dissoluta*. *J Org Chem* **55**:4912–4915.
- Hamel E and Lin CM (1984) Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. *Biochemistry* **23**:4173–4184.
- Hood KA, West LM, Rouwe B, Northcote PT, Berridge MV, Wakefield SJ, and Miller, JH (2002) Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. *Cancer Res* **62**:3356–3360.
- Howard J and Hyman AA (2003) Dynamics and mechanics of the microtubule plus end. *Nature* **422**:753–758.
- Jordan MA and Wilson L (2004) Microtubules as a target for anticancer drugs. *Nat Rev Cancer* **4**:253–265.
- Jung WH, Harrison C, Shin Y, Fournier JH, Balachandran R, Raccor BS, Sikorski RP, Vogt A, Curran DP, and Day BW (2007) Total synthesis and biological evaluation of C16 analogs of (–)-dictyostatin. *J Med Chem* **50**:2951–2966.
- Kowalski RJ, Giannakakou P, and Hamel E (1997b) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). *J Biol Chem* **272**:2534–2541.
- Madiraju C, Edler MC, Hamel E, Raccor BS, Balachandran R, Zhu G, Giuliano KA, Vogt A, Shin Y, Fournier JH, et al. (2005) Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. *Biochemistry* **44**:15053–15063.
- Minguez JM, Kim SY, Guillano KA, Balachandran R, Madiraju C, Day BW, and Curran DP (2003) Synthesis and biological assessment of simplified analogues of the potent microtubule stabilizer (+)-discodermolide. *Bioorg Med Chem* **11**:3335–3357.
- Mooberry SL, Tien G, Hernandez AH, Plubrukarn A and Davidson BS (1999) Lauilimalide and isolauilimalide, new paclitaxel-like microtubule-stabilizing agents. *Cancer Res* **59**:653–660.
- Morton MF, Harper EA, Tavares IA, and Shankley NP (2002) Pharmacological evidence for putative CCK1 receptor heterogeneity in human colon smooth muscle. *Br J Pharmacol* **136**:873–882.
- Motulsky H and Christopoulos A (2003) Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting. GraphPad Software Inc., San Diego, CA.
- Padron JA, Carrasco R, and Pellon RF (2002) Molecular descriptor based on a molar refractivity partition using Randic-type graph-theoretical invariant. *J Pharm Sci* **5**:258–265.
- Paterson I, Britton R, Delgado O, Meyer A, and Poullennec KG (2004a) Total synthesis and configurational assignment of (–)-dictyostatin, a microtubule-stabilizing macrolide of marine sponge origin. *Angew Chem Int Ed Engl* **43**:4629–4633.
- Paterson I, Britton R, Delgado O, and Wright AE (2004b) Stereochemical determination of dictyostatin, a novel microtubule-stabilising macrolide from the marine sponge *Corallistidae* sp. *Chem Commun (Camb)* 632–633.
- Paterson I and Gardner NM (2007) Design, synthesis and biological evaluation of a macrocyclic discodermolide/dictyostatin hybrid. *Chem Commun (Camb)* 49–51.
- Paterson I, Gardner NM, Poullennec KG, and Wright AE (2007) Synthesis and biological evaluation of novel analogues of dictyostatin. *Bioorg Med Chem Lett* **17**:2443–2447.
- Pettit GR, Cichacz ZA, Gao F, Boyd MR, and Schmidt JM (1994) Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. *J Chem Soc Chem Commun* 1111–1112.
- Pryor DE, O'Brate A, Bilcer G, Diaz JF, Wang Y, Wang Y, Kabaki M, Jung MK, Andreu JM, Ghosh AK, et al. (2002) The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. *Biochemistry* **41**:9109–9115.
- Reese M, Sánchez-Pedregal VM, Kubicek K, Meiler JM, Blommers MJJ, Griesinger C, and Carlomagno T (2007) Structural basis of the activity of the microtubule-stabilizing agent epothilone A studied by NMR spectroscopy in solution. *Angew Chem Int Ed Engl* **46**:1864–1868.
- Sato B, Muramatsu H, Miyauchi M, Hori Y, Takase S, Hino M, Hashimoto S, and Terano H (2000) A new antimitotic substance, FR182877. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. *J Antibiot (Tokyo)* **53**:123–130.
- Schiff PB, Fant J, and Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. *Nature* **277**:665–667.
- Shin Y, Fournier JH, Fukui Y, Bruckner AM, and Curran DP (2004) Total synthesis of (–)-dictyostatin: confirmation of relative and absolute configurations. *Angew Chem Int Ed Engl* **43**:4634–4637.
- Shin Y, Fournier JH, Balachandran R, Madiraju C, Raccor BS, Zhu G, Edler MC, Hamel E, Day BW, and Curran DP (2005) Synthesis and biological evaluation of (–)-16-normethyl dictyostatin: a potent analogue of (–)-dictyostatin. *Org Lett* **7**:2873–2876.
- Shin Y, Fournier JH, Bruckner A, Madiraju C, Balachandran R, Raccor BS, Edler MC, Hamel E, Sikorski RP, Vogt A, et al. (2007) Synthesis and biological evaluation of (–)-dictyostatin and stereoisomers. *Tetrahedron* **63**:8537–8562.
- Smith AB 3rd, LaMarche MJ, and Falcone-Hindley M (2001) Solution structure of (+)-discodermolide. *Org Lett* **3**:695–698.
- Smith AB 3rd, Freeze BS, LaMarche MJ, Hirose T, Brouard I, Xian M, Sundermann KF, Shaw SJ, Burlingame MA, Horwitz SB, et al. (2005) Design, synthesis, and evaluation of analogues of (+)-14-normethyl discodermolide. *Org Lett* **7**:315–318.
- Swillens S (1995) Interpretation of binding curves obtained with high receptor concentrations: Practical aid for computer analysis. *Mol Pharmacol* **47**:1197–1203.
- Verdier-Pinard P, Lai JY, Yoo HD, Yu J, Marquez B, Nagle DG, Nambu M, White JD, Falck JR, Gerwick WH, et al. (1998) Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. *Mol Pharmacol* **53**:62–76.
- Xia S, Kenesky CS, Rucker PV, Smith AB, Orr GA, and Horwitz SB (2006) A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin. *Biochemistry* **45**:11762–11775.

**Address correspondence to:** Dr. Billy W. Day, 10017 Biomedical Science Tower 3, 3501 Fifth Avenue, Pittsburgh, PA 15213. E-mail: bday@pitt.edu